The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Or better still Count Arthur Strong, have more chance of predicting the P3 RNS than charts and chartists in my very humble opinion.
There, I said it !
It will fall when Marsden and the team are good and ready and will have b.ugger all to do with the market .
Doc,the high blip at the start was me bending down to untie my shoes .
SP graph today looks similar to my heart rate graph during sex .
Cabin fever certainly seems to have affected this BB ,but you can't really use RM and SSH as model examples as they receive salaries in excess of £250k per annum to maintain their dignity.They will still receive these high salaris should ( God forbid) the sprinter trial fails . All attention will then be directed to COPD and monies will be raised to fund this P3 and maintain their lifestyle. The only thing in real jeapody for those two fellows are their childrens inheritance given SSH age and career and RMs 19 years of top earnings at Synairgen .
Many ( including myself) have a lot more to lose but agreed ,there's absolutely no excuse for the inhouse back biting on here of late .
Good luck everyone .and ffs calm down .
I've still got that "Watneys party 7" I've been saving for a sunny day .
Volumes would indicate there is lots of interest but reality seems to favour that the bots are constantly buy ,selling buying selling the same tranche of shares to control the SP.
I doubt it is so straight forward but I really have no idea whats going on .
The recent drop looks like it was orchastrated to accomadate todays RNS .Two straight lines of trading with a blip to separate them at noon .
Stick me on the list are ( thought I was already on it.I still have a Watneys party 7 in a cupboard somewhere, I could bring .
To be perfectly honest SD , last 5 ( and I'm only tell you so keep it to yourself).
Personally I am disapointed in the agenda for this RNS . It appears to be a rehash of old news which gives out a wiff of desperation .To include the word" Delta" amongst the variants would have sent out a strong signal to the markets unless ofcourse you are bang on the money .
Even myself, have tiny doubts niggling away now because of that RNS .There was simply no need for it nor the presentation .I doubt there are any health authorities or governments who are unaware of Synairgens drug and impending results . We shall see. The Sp hasn't crashed so I am probably way off the mark ,but didn't expect that RNS and its content.
I bet you knew Bruce Willis was a ghost after 5 mins ya rascal
I just pray to the gods that the " ZIPPOS" don't get the "RONA"
( they look just like Hippos only they are a " LITTLE LIGHTER")
Exactly ,I am from gorton ,now live in the Netherlands and won't be selling my 64k shares for 3 squid as that's where it will take me if I do lol
Sincerely hope so ,I'm dying to sell up and retire to longsight, manchester
Woodford was a significant investor in synairgen through his patient capital fund , as well as nanapore ,atom Bank etc so makes perfect sense that he would dive straight back in .
Glad you seen the funny side SD lol .All the very best .
I will only accept Sharedealers take on this ,
He sees dead people .
Why would synairgen lay bare all their cards on the table at this point ,Sure ,get approvals and orders and repay the shareholders then let someone else decide if. 001 is less effective than other drugs .
Don't see Az ,Moderna ,gillead,etc lining up virus mutations just to prove their drugs don't really work .
No apologies necessary at all Ndl.i am on a learning curve here and bow to your superior knowledge .
Scarramouche ,I can't give that info but I was led to believe half of the trial was assessed for futility. I have totally guessed that 40% is derisked because the decision to proceed was a yes rather than no ( based on 50% of trial size).Apologies if misleading but apparently someone knows half the trial results already but not target specific .
NDN, . Are we not then in fact only awaiting news on 305 patients given that unblinded raw data was already examined previously to assess futility in accordance with P3 protocol ?
Ofcourse Synairgen havnt seen those early indications so have to start from scratch when producing top line results .
However , the futility appraisal must have derisked the trial by 40 + % no ? .